The Insider Summary
- What it is
- A synthetic analog of growth hormone-releasing factor (GHRH 1–44), marketed as Egrifta. It stimulates the pituitary to release growth hormone.
- Why researchers are interested
- It is the proof of concept for the whole GHRH-analog class: pituitary-level stimulation, carried through pivotal trials to approval, with visceral adipose tissue as a measured clinical endpoint.
- Evidence
- Clinical. A published pivotal programme including a randomised placebo-controlled trial in the New England Journal of Medicine, plus the full FDA review that supported approval.
- Regulatory status
- FDA approved — for one narrow indication only: reduction of excess abdominal fat in adults with HIV and lipodystrophy. The label states explicitly that it is not indicated for weight loss management and that long-term cardiovascular safety has not been established.
- Bottom line
- Tesamorelin shows what an actual approval looks like: a specific population, a specific measured outcome, an explicit list of what the drug is not for, and a set of monitoring requirements. Every other GHRH-class compound discussed online is being compared, implicitly, against this standard — and none of them meet it.
Quick reference
- Compound
- Peptide analog
- Research areas
- Growth Hormone & Endocrine ResearchMetabolic Research
- Evidence level
- CLINICAL
- Research status
- FDA Approved
- FDA approved
- Yes — for reduction of excess abdominal fat in adults with HIV and lipodystrophy
- Human clinical evidence
- Extensive
- Sequence
A trans-3-hexenoyl derivative of human growth hormone-releasing factor 1–44- Last reviewed
- 17 September 2026
What is tesamorelin?
Tesamorelin is a modified version of the first 44 amino acids of human growth hormone-releasing factor. The modification — a trans-3-hexenoyl group at the N-terminus — makes the molecule more resistant to enzymatic degradation than the native hormone.
It was developed specifically for HIV-associated lipodystrophy, a condition in which antiretroviral therapy is associated with redistribution of body fat, including accumulation of visceral adipose tissue around the abdominal organs. Visceral fat is metabolically distinct from subcutaneous fat, and its accumulation is associated with adverse metabolic and cardiovascular markers — which is why reducing it was a plausible therapeutic target.
A newer formulation, tesamorelin F8 (Egrifta WR), has since received FDA approval for the same clinical problem.
What is tesamorelin approved for — and what is it not approved for?
The approved indication reads: a growth hormone releasing factor analog "indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" [1].
The label's Limitations of Use section is equally important, and states plainly that:
- long-term cardiovascular safety has not been established;
- the drug is not indicated for weight loss management, and its effect on weight is neutral;
- there is no evidence that it improves compliance with antiretroviral therapy.
This is what a regulator writes when it has reviewed the evidence and wants to prevent extrapolation. A compound approved to reduce visceral adipose tissue in one specific population is not thereby a weight-loss drug, an anti-ageing drug, or a body-composition drug for the general population.
How does Tesamorelin work?
Tesamorelin binds growth hormone-releasing hormone receptors on pituitary somatotrophs, stimulating endogenous growth hormone synthesis and release, which raises IGF-1. In people with HIV-associated lipodystrophy, this produces a preferential reduction in visceral adipose tissue. The trans-3-hexenoyl modification improves stability relative to native GHRF, giving a duration of action suitable for once-daily subcutaneous dosing.
Research and clinical evidence
The table below grades the published record separately for each research area, because a compound can be well studied in one context and entirely unstudied in another. Grades follow the Peptide Insider evidence taxonomy.
| Research area | Evidence level | What the published record shows |
|---|---|---|
| HIV-associated lipodystrophy (visceral adipose tissue) | CLINICAL | Randomised placebo-controlled pivotal trials demonstrating reduction in visceral adipose tissue, supporting FDA approval in 2010. |
| Cardiovascular outcomes | INSUFFICIENT | The FDA label states explicitly that long-term cardiovascular safety has not been established. Visceral fat reduction is a surrogate; outcome data do not exist. |
| Weight loss in the general population | INSUFFICIENT | Not an approved use. The label states the drug is not indicated for weight loss management and that its weight effect is neutral. |
Human clinical studies
Studies conducted in people. These carry the most weight, and their absence is itself a finding.
Metabolic effects of a growth hormone-releasing factor in patients with HIV[2]
2007- Design
- Randomised, double-blind, placebo-controlled multicentre trial
- Population
- Adults with HIV and abdominal fat accumulation
FindingsTreatment with tesamorelin reduced visceral adipose tissue relative to placebo, with associated changes in lipid parameters. This trial formed part of the pivotal programme supporting FDA approval.
LimitationsConducted in a specific population — adults with HIV and lipodystrophy — with an imaging-based surrogate endpoint. Results do not generalise to people without that condition, and the programme did not measure long-term cardiovascular outcomes.
FDA and regulatory status
Tesamorelin is approved by the FDA. The approval is indication-specific: reduction of excess abdominal fat in adults with HIV and lipodystrophy [1].
The prescribing information carries warnings and precautions that are directly relevant to any discussion of growth hormone axis stimulation generally:
- Neoplasms. Growth hormone is a growth factor; patients with active malignancy should not be treated, and pre-existing malignancies must be inactive before therapy begins.
- IGF-1 elevation. The label states that the effects of prolonged elevations in IGF-1 are unknown, and requires monitoring, with discontinuation recommended for persistent elevation.
- Fluid retention, including oedema, arthralgia and carpal tunnel syndrome.
- Glucose intolerance and diabetes, with baseline and periodic monitoring required.
- Hypersensitivity reactions, reported in approximately 4% of clinical trial patients.
- Increased mortality in acute critical illness, a class consideration for growth hormone effects.
Those warnings exist on the one approved product in this class. They are the most concrete safety information available for GHRH-analog pharmacology, and they are worth reading before evaluating claims made about unapproved compounds that work the same way.
Safety and known risks
Risks are separated into what is documented, what is plausible but unestablished, and what has not been studied. The third column is usually the longest one for an unapproved compound, and it is not a reassurance.
Known risks
Documented in regulatory labelling or published trial safety data.
- Increased risk of neoplasms — contraindicated in active malignancy; pre-existing malignancies must be inactive before treatment.
- Elevated IGF-1, with the label stating that the effects of prolonged elevation are unknown and requiring monitoring.
- Fluid retention: oedema, arthralgia, carpal tunnel syndrome.
- Glucose intolerance and new-onset diabetes mellitus; baseline and periodic glucose monitoring required.
- Hypersensitivity reactions in approximately 4% of clinical trial patients.
- Consideration for discontinuation in acute critical illness due to increased mortality observed with growth hormone effects.
Potential risks
Plausible on mechanism or drug-class grounds, but not established for this compound.
- Long-term cardiovascular safety has not been established — stated as a Limitation of Use on the label.
Unknown or insufficiently studied
Questions the published record does not currently answer.
- Effects of long-term use beyond the durations studied in the approval programme.
- Effects in populations outside the approved indication have not been established.
Frequently asked questions
Is tesamorelin FDA approved?
Is tesamorelin a weight loss drug?
How does tesamorelin compare to CJC-1295?
What are the main warnings on the tesamorelin label?
Continue reading
Comparison
Tesamorelin vs CJC-1295
Two GHRH analogs with the same upstream mechanism and completely different evidence. What separates an approved medicine from a discontinued research compound.
Regulation
Are Peptides FDA Approved?
Some peptides are FDA approved drugs. Most compounds sold as "peptides" are not. Here is how to tell the difference, and what approval does and does not mean.
Regulation
Investigational vs Approved Peptides
Investigational, approved, discontinued and unstudied are four different states, and compounds in all four are sold side by side. How to tell them apart.
References
Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.
- 1.U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) — Highlights of Prescribing Information. FDA Drugs@FDA, 2019;NDA 022505.Regulatory
- 2.Falutz J, Allas S, Blot K, et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 2007;357(23):2359–2370.